The Brazilian Oswaldo Cruz Foundation (Fiocruz) announced today that it intends to develop an oral drug against Covid-19
“Fiocruz, in alliance with the Microbiological company and the Center for Innovation and Preclinical Testing (CIEnP), seeks to develop an antiviral for oral use against Covid-19,” he said in a statement.
The substance, called MB-905, was purified from kinetin “and proved to be effective in inhibiting the replication of SARS-CoV-2 in human liver and lung cell lines, in addition to helping to slow down the inflammatory process triggered by the virus.” ”. , detailed the Brazilian foundation.
The information was sent to the National Health Surveillance Agency (Anvisa) of Brazil and now the foundation awaits the approval of this government agency to start the first phase of clinical trials.
Source: TSF
